LILRB2 promotes immune escape in breast cancer cells via enhanced HLA-A degradation.

IF 6.6 2区医学 Q1 Medicine

Cellular Oncology Pub Date : 2024-04-24 DOI:10.1007/s13402-024-00947-5

Zhiyuan Jiang, Qianru Huang, Yujie Chang, Yiran Qiu, Hao Cheng, Mengdi Yang, Shunyi Ruan, Suyuan Ji, Jing Sun, Zhi-yu Wang, Shengyuan Xu, Rui Liang, Xueyu Dai, Kejin Wu, Bin Li, Dan Li, Hui Zhao

引用次数: 0

Abstract Image

查看原文本刊更多论文

LILRB2 通过增强 HLA-A 降解促进乳腺癌细胞的免疫逃逸。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

10.40

自引率

1.50%

发文量

审稿时长

16 weeks

期刊介绍： The Official Journal of the International Society for Cellular Oncology Focuses on translational research Addresses the conversion of cell biology to clinical applications Cellular Oncology publishes scientific contributions from various biomedical and clinical disciplines involved in basic and translational cancer research on the cell and tissue level, technical and bioinformatics developments in this area, and clinical applications. This includes a variety of fields like genome technology, micro-arrays and other high-throughput techniques, genomic instability, SNP, DNA methylation, signaling pathways, DNA organization, (sub)microscopic imaging, proteomics, bioinformatics, functional effects of genomics, drug design and development, molecular diagnostics and targeted cancer therapies, genotype-phenotype interactions. A major goal is to translate the latest developments in these fields from the research laboratory into routine patient management. To this end Cellular Oncology forms a platform of scientific information exchange between molecular biologists and geneticists, technical developers, pathologists, (medical) oncologists and other clinicians involved in the management of cancer patients. In vitro studies are preferentially supported by validations in tumor tissue with clinicopathological associations.